---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031157"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:09:16.528676+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Indaptus Q2 net loss $0.47/sh; cash $7.3M; raises $3M in August offering

## Summary
- Net loss per share $0.47 for Q2 2024 vs $0.39 YoY; six-month loss $0.92 vs $0.89.
- Cash and equivalents $7.3M at June 30, 2024; raised $3.0M (net ~$2.5M) on August 8 via registered direct offering and private placement.
- Phase 1 Decoy20 trial: completed one month of weekly dosing in 3 patients at 3x10^7 dose; single dose at 7x10^7 completed.
- Presented Decoy20 data at AACR and ASCO; CSO Michael Newman chaired STING & TLR Summit.
- Cash runway expected into Q1 2025 based on current operations.

## SEC filing metadata
- accession: 0001493152-24-031157
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315224031157/0001493152-24-031157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315224031157/form-8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031157
- JSON: https://secwatch.observer/filing/0001493152-24-031157.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.